Anticancer Research

31/07/2021

🥳 Anticancer Research is now 40 years old!

ℹ AR is an international, peer-reviewed monthly journal designed to rapidly publish original and review papers on experimental and clinical cancer research.
📈 Impact factor (2020): 2.48

23/01/2021

The use of genomics databases and information-theoretical analyses can prove powerful methods, able to help identify molecules with the potential to effectively serve as prognosis markers and/or molecular targets for the treatment of various forms of cancer.

Using genomics databases and siRNA technology, a group from Tokyo University of Science (Onaga C., Shoma Tamori, Motomura H., et. al.; Anticancer Res., vol. 41, January 2021), identified SLC20A1 as a potential prognostic marker and therapeutic target in estrogen receptor-positive, claudin-low and basal-like breast cancers, as SLC20A1-high patients showed poor prognoses and poor response to radiotherapy.



Read the full (open-access) article here:
https://ar.iiarjournals.org/content/41/1/43.full

Background/Aim: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. Materials and Methods: Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockd...

10/01/2021

The new Anticancer Research issue is now online.

http://ar.iiarjournals.org/content/current

19/11/2020

Read about how cancer immunotherapy influenced COVID-19 vaccine development:

CRI Fellow Susan Klaeger, Ph.D., is optimizing a method to identify which antigens make the best targets for vaccines.

11/11/2020

In a review that was published in the latest issue of AR, Partynska et al. 2020, presents the dual role of zyxin, a focal adhesion protein, in the progression of carcinogenesis, as a tumor suppressor in certain types of cancer, and as an oncogene in others. It highlights the concept of cancer type-specific effects of various proteins, revealing the complexity of carcinogenesis.
The full article can be found here: http://ar.iiarjournals.org/content/40/11/5981.full

Zyxin (ZYX) is a LIM domain protein whose presence has been detected in the cytoplasm and nucleus. ZYX can translocate between these two compartments and therefore, can take part in the regulation of various cellular processes. VASP and α-actinin are examples of proteins that interact with ZYX. As ...

05/11/2020

A study published by the group of Professor James Connor, (Penn State University) in the latest issue of Anticancer Research identified a barbituric acid analog and 2 thiobarbituric acid analogs as effective antitumor compounds. The compounds were found to exhibit efficacy in both in vitro and in vivo lung cancer mouse tumor models.

The whole study can be accessed here:

https://lnkd.in/dj5ptMN

Background/Aim: Previously, we reported the identification of a cytotoxic chemotype compound CC-I (1a), a derivative of thiobarbituric acid. We also reported the anticancer activity of a series of novel thio- and seleno-barbituric acid analogs. Materials and Methods: We herein evaluated the effect o...

04/07/2020

Our July issue of Anticancer Research is now online.
Happy 4th of July to our US-based friends!
http://ar.iiarjournals.org/content/40/7.toc

27/06/2020

Combination of vitamin D with paclitaxel and carboplatin inhibits the growth of ovarian cancer cells in vitro.

Read the full study published from researchers in Tampere University hospital, here:

http://ar.iiarjournals.org/content/40/6/3129.full?sid=19579f69-a48a-4972-bbb7-c710b022b718

Background/Aim: The combination of paclitaxel and carboplatin is the standard chemotherapy for ovarian cancer. Previous studies have implied that vitamin D (1,25-D3) may have growth inhibitory effects in ovarian cancer. This study aimed to investigate the effect of paclitaxel, carboplatin and 1,25-D...

12/06/2020

Approach to identifying the best drug targets gets critical test

06/06/2020

An interesting study revealing new potential biomarkers of pancreatic cancer, published in the latest AR issue. You can read it here:

http://ar.iiarjournals.org/content/40/6/3109.full

Background/Aim: Pancreatic cancer is one of the deadliest forms of cancer and ranks among the leading causes of cancer-related death worldwide. The most common histological type is ductal adenocarcinoma (PDAC), accounting for approximately 95% of cases. Deregulation of protein synthesis has been fou...

04/06/2020

Our June issue of Anticancer Research (Volume 40, Issue 6) is now live and you may have a look at the contents here:
http://ar.iiarjournals.org/content/40/6

07/05/2020

Our May issue of Anticancer Research is published and you may have a look at the contents here:
http://ar.iiarjournals.org/content/40/5

02/05/2020

Potential of exo-miRNA biomarkers in pancreatic cancer prognosis.

http://ar.iiarjournals.org/content/40/4/1843.abstract

Background/Aim: Epithelial-to-mesenchymal transition (EMT) plays important roles in cancer progression. This study aimed to identify the exosomal miRNA (exo-miRNA) profiles related to the EMT status in pancreatic cancer (PC). Materials and Methods: Comprehensive exo-miRNA-expression profiles in the....

25/04/2020

During the current pandemic, efficient sharing of information is extremely important. For this reason, all articles for the Covid-19 Special Issue will be uploaded on our website ahead of print as soon as they have been peer-reviewed. The issue will be formally published in June 2020 and will be accessible on In Vivo’s website through Highwire Press.

https://iiar-anticancer.org/in-vivo-special-issue/

19/04/2020

An informative description of immunotherapy against cancer by the CRI.

https://www.cancerresearch.org/immunotherapy/treatment-types/adoptive-cell-therapy

Adoptive cell therapy is a type of cancer treatment that reactivates, enhances, and expands naturally occurring, cancer-fighting immune cells before re-infusing them into patients.

08/04/2020

PTC209: A novel chemotherapeutic agent with potential in cervical cancer therapy. A new study by Dr. Junan Li and his team at The Ohio State University College of Pharmacy. You may find it here:
http://ar.iiarjournals.org/content/40/1/133.abstract

31/03/2020

Back to basics: Prevention is the best cure.

https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/cancer-prevention/art-20044816

Real-life strategies to reduce your risk of cancer.

27/03/2020

While the world is overwhelmed with the Covid-19 pandemic, many people with various illnesses may feel more scared and insecure regarding their treatments. This is another reason to respect the social distancing measures applied worldwide, in order to let hospitals "breathe" and deal with everyone in need of treatment or hospitalization.

A nice article worth a read here:

https://www.nhpr.org/post/when-cancer-and-coronavirus-collide-fear-and-resilience /0

It's like being in prison inside a prison. Having advanced cancer while being wary of the COVID-19 virus really sucks. I am speaking both as a doctor

07/03/2020

CAR-T cells built with scorpion venom against cancer cells!

https://stm.sciencemag.org/content/12/533/eaaw2672

Chlorotoxin derived from scorpion venom has previously been shown to bind glioblastoma cells. Wang et al. designed a chimeric antigen receptor (CAR) based on chlorotoxin to surmount limitations of other glioblastoma-targeted CARs that have not been able to overcome tumor heterogeneity and antigen es...

05/03/2020

Our March issue of Anticancer Research is already out and you may check its contents here:
http://ar.iiarjournals.org/content/current

29/02/2020

https://www.curetoday.com/articles/4-things-patients-with-cancer-should-know-about-coronavirus-2019

Patients with a compromised immune system are more susceptible to the coronavirus, including those with cancer. Here are four key things patients with cancer should know about the novel coronavirus.

02/02/2020

Cancer development in humans may also be interpreted as an evolutionary process, which in many ways mirrors the evolution of species.

A recent review published in Anticancer Research discusses cancer evolution and progression in relation to Darwinism.

http://ar.iiarjournals.org/content/39/1/1.full

Our review compares evolution of cancer in the human body to the origin of new species from a common ancestor organism with respect to the theory of Charles Darwin. Moreover, the functional role of the tumor microenvironment as a selective pressure actively participating in cancer progression is als...

23/01/2020

https://www.sciencedaily.com/releases/2020/01/200120113130.htm

Researchers tested approximately 4,518 drug compounds on 578 human cancer cell lines and found nearly 50 that have previously unrecognized anti-cancer activity. These drugs have been used to treat conditions such as diabetes, inflammation, alcoholism, and even arthritis in dogs. The findings suggest...

05/11/2019

We' re right here at Table 11 at the 2019 Charleston Conference. Come talk to us and discover all the ways you can access Anticancer Research!

05/11/2019

Come find us at the 2019 Charleston Vendor Showcase!
We will be happy to meet you in person and showcase our new Android and iOS apps for all three of our journals. Also you can get a USB stick with an exclusive subscription offer for Anticancer Research. We will be welcoming you at Table 11.

14/10/2019

Now you can access Anticancer Research
with ease on your Android© phone or tablet with our newly designed app, freely available on Google Play Store

https://play.google.com/store/apps/details?id=com.slidescenter.journalapp.ar&hl=en

14/10/2019

03/10/2019

Our October issue is out and can be found here:
http://ar.iiarjournals.org/content/39/10